Top Ankylosing Spondylitis Treatment Companies

Global Ankylosing Spondylitis Treatment Market size was valued at USD 3.34 Billion in 2024 and is poised to grow from USD 3.6 Billion in 2025 to USD 6.57 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026–2033).

Global ankylosing spondylitis treatment market competition is characterized by innovation-fostered competition among major players such as AbbVie Inc., Pfizer Inc., Eli Lilly and Company, Novartis AG, and Johnson & Johnson. Firms emphasize biologic innovation, increasing biosimilar offerings, and strategic collaborations. AbbVie leverages Humira's heritage while driving Rinvoq forward, while Novartis fortifies market presence with Cosentyx and aggressive participation in clinical trials for the next-generation IL-17 inhibitors. 'AbbVie Inc. (U.S.) ', 'Novartis AG (Switzerland) ', 'Johnson & Johnson (U.S.) ', 'Pfizer Inc. (U.S.) ', 'Amgen Inc. (U.S.) ', 'UCB S.A. (Belgium) ', 'Bristol-Myers Squibb (U.S.) ', 'Eli Lilly and Company (U.S.) ', 'Roche Holding AG (Switzerland) ', 'Merck & Co., Inc. (U.S.) ', 'Biogen Inc. (U.S.) ', 'Celgene Corporation (U.S.) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Bayer AG (Germany) ', 'Regeneron Pharmaceuticals (U.S.) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Sandoz International GmbH (Switzerland) ', 'Lupin Limited (India) ', 'Mylan N.V. (U.S.)'

The increasing global prevalence of ankylosing spondylitis, particularly among younger populations, is a major driver. This increase in diagnosed cases is driving demand for effective treatments, and healthcare systems and pharmaceutical firms are investing more in drug development, diagnostic technologies, and patient-focused care strategies to address increasing therapeutic demands.

Biologics Innovation Driving Therapeutic Evolution: The transition to biologics, such as TNF and IL-17 inhibitors, is revolutionizing ankylosing spondylitis therapy by providing targeted therapies with better efficacy. Ongoing R&D and growing biosimilar portfolios are driving market growth, as providers and patients increasingly prefer biologics for long-term disease management and enhanced quality of life.

North America holds a dominant position in the global ankylosing spondylitis treatment market due to advanced healthcare infrastructure, high awareness, and early adoption of biologics. The region is supported by robust R&D investments, good reimbursement policies, and the presence of big pharmaceutical companies. Rising incidence of autoimmune diseases, along with ongoing innovation in drug discovery and targeted therapies, further consolidates North America's market leadership and growth prospects in ankylosing spondylitis treatment.